Stephens Inc. AR lessened its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 18.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 307,413 shares of the company’s stock after selling 70,386 shares during the period. Stephens Inc. AR owned 0.45% of Myriad Genetics worth $7,944,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of MYGN. BlackRock Inc. grew its stake in shares of Myriad Genetics by 168,335.7% during the first quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock worth $183,203,000 after acquiring an additional 9,536,219 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Myriad Genetics by 59.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,642,820 shares of the company’s stock worth $50,742,000 after acquiring an additional 987,966 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Myriad Genetics by 16.8% during the first quarter. Vanguard Group Inc. now owns 6,251,030 shares of the company’s stock worth $120,020,000 after acquiring an additional 897,287 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Myriad Genetics by 131.2% during the first quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock worth $17,632,000 after acquiring an additional 521,146 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Myriad Genetics by 4,174.4% during the first quarter. Principal Financial Group Inc. now owns 530,148 shares of the company’s stock worth $10,179,000 after purchasing an additional 517,745 shares during the period.

MYGN has been the subject of a number of research reports. Deutsche Bank AG raised Myriad Genetics from a “sell” rating to a “hold” rating and decreased their target price for the stock from $27.86 to $15.00 in a report on Friday, August 18th. BidaskClub downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Zacks Investment Research downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. J P Morgan Chase & Co reaffirmed an “underweight” rating and set a $16.00 target price on shares of Myriad Genetics in a report on Friday, June 30th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $22.00 target price on shares of Myriad Genetics in a report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. Myriad Genetics presently has a consensus rating of “Hold” and an average target price of $21.22.

TRADEMARK VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/11/stephens-inc-ar-has-7-94-million-holdings-in-myriad-genetics-inc-mygn.html.

Shares of Myriad Genetics, Inc. (NASDAQ MYGN) traded down 1.17% on Monday, hitting $32.15. The stock had a trading volume of 269,709 shares. The company has a market cap of $2.20 billion, a price-to-earnings ratio of 100.78 and a beta of 0.26. Myriad Genetics, Inc. has a one year low of $15.15 and a one year high of $33.42. The firm’s 50-day moving average is $27.61 and its 200-day moving average is $22.79.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.04. The firm had revenue of $200.50 million during the quarter, compared to analysts’ expectations of $193.71 million. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. Myriad Genetics’s revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.36 earnings per share. On average, analysts expect that Myriad Genetics, Inc. will post $1.02 EPS for the current fiscal year.

In related news, Director John T. Henderson sold 30,000 shares of Myriad Genetics stock in a transaction on Friday, September 1st. The stock was sold at an average price of $30.30, for a total transaction of $909,000.00. Following the completion of the transaction, the director now directly owns 52,524 shares of the company’s stock, valued at $1,591,477.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 6.20% of the company’s stock.

Myriad Genetics Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Stock Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related stocks with our FREE daily email newsletter.